Vimarsana
Biggest News Aggregation in the World

Page 3 - Hartmutj Ehrlich News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Hartmutj Ehrlich. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Hartmutj Ehrlich Today - Breaking & Trending Today

Abivax reports 2022 financial results and operations update - Vimarsana News

Abivax reports 2022 financial results and operations update

EQS-News: ABIVAX / Key word(s): Annual ResultsAbivax reports 2022 financial results and operations update 19.04.2023 / 21:00 CET/CESTThe issuer is solely responsible for the content of this announcement.Abivax reports 2022 financial results and operations update Obefazimod global pivotal phase 3 program (ABTECT...

Abivax Appoints Michael Ferguson as Chief Commerical Officer - Vimarsana News

Abivax Appoints Michael Ferguson as Chief Commerical Officer

Michael Ferguson has a strong track record in the biopharmaceutical industry, having held senior positions for commercialization and marketing of drugs in the field of Gastroenterology and specifically

Abivax appoints Michael Ferguson as Chief Commerical Officer - Vimarsana News

Abivax appoints Michael Ferguson as Chief Commerical Officer

EQS-News: ABIVAX / Key word: Personnel Abivax appoints Michael Ferguson as Chief Commerical Officer 18.04.2023 / 18:00 CET/CEST The issuer is solely responsible for the content... | April 18, 2023

Abivax Reports Two-Year Efficacy and Safety Data of Obefazimod Phase ... - Vimarsana News

Abivax Reports Two-Year Efficacy and Safety Data of Obefazimod Phase ...

Abivax Reports Two-Year Efficacy and Safety Data of Obefazimod Phase ...

Abivax Reports Two-Year Efficacy and Safety Data of Obefazimod Phase 2b Maintenance Trial in Ulcerative Colitis - Vimarsana News

Abivax Reports Two-Year Efficacy and Safety Data of Obefazimod Phase 2b Maintenance Trial in Ulcerative Colitis

The analysis demonstrates clinical remission in 52.5% (n=114) of 217 moderate to severe ulcerative colitis (UC) patients (intent-to-treat population, ITT) after two years (96 weeks) of once-daily oral